Market Research Logo

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015’, provides an overview of the Chemotherapy Induced Nausea and Vomiting’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Nausea and Vomiting, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Nausea and Vomiting and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chemotherapy Induced Nausea and Vomiting and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chemotherapy Induced Nausea and Vomiting products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chemotherapy Induced Nausea and Vomiting pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Nausea and Vomiting Overview
Therapeutics Development
Pipeline Products for Chemotherapy Induced Nausea and Vomiting - Overview
Pipeline Products for Chemotherapy Induced Nausea and Vomiting - Comparative Analysis
Chemotherapy Induced Nausea and Vomiting - Therapeutics under Development by Companies
Chemotherapy Induced Nausea and Vomiting - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Chemotherapy Induced Nausea and Vomiting - Products under Development by Companies
Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development
Acacia Pharma Limited
Aphios Corporation
Astellas Pharma Inc.
Helsinn Healthcare S.A.
Heron Therapeutics, Inc.
INSYS Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Merck & Co., Inc.
RedHill Biopharma Ltd.
SoluBest Ltd.
Suda Ltd
Teikoku Pharma USA, Inc.
Tesaro, Inc.
Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(netupitant + palonosetron hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APD-403 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FK-886 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
granisetron ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
granisetron hydrochloride ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
netupitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ondansetron hydrochloride CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rolapitant hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TPW-146 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chemotherapy Induced Nausea and Vomiting - Recent Pipeline Updates
Chemotherapy Induced Nausea and Vomiting - Dormant Projects
Chemotherapy Induced Nausea and Vomiting - Discontinued Products
Chemotherapy Induced Nausea and Vomiting - Product Development Milestones
Featured News & Press Releases
Aug 17, 2015: Insys Therapeutics' Dronabinol Oral Solution NDA Accepted for Filing by FDA
Jul 20, 2015: Heron Therapeutics Resubmits SUSTOL New Drug Application to FDA
Jun 29, 2015: Merck Announces Phase 3 Study of Single-Dose EMEND (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
Jun 25, 2015: TESARO Announces Six Abstracts To Be Presented At The 2015 Multinational Association Of Supportive Care In Cancer Annual Meeting
Jun 02, 2015: The European Commission Approves Helsinn's Akynzeo for the Prevention of Chemotherapy Induced Nausea and Vomiting in the European Union
Jun 02, 2015: Insys Therapeutics Submits NDA for Dronabinol Oral Solution
Jun 01, 2015: New cancer therapy study results - MAGIC Trial
May 30, 2015: TESARO Announces Successful Completion of Rolapitant Bioequivalence Study
May 28, 2015: Heron Therapeutics Announces Positive Results from Phase 3 MAGIC Study of SUSTOL
May 20, 2015: Helsinn Group to present data on Akynzeo at 2015 ASCO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2015
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Limited, H2 2015
Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corporation, H2 2015
Chemotherapy Induced Nausea and Vomiting - Pipeline by Astellas Pharma Inc., H2 2015
Chemotherapy Induced Nausea and Vomiting - Pipeline by Helsinn Healthcare S.A., H2 2015
Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics, Inc., H2 2015
Chemotherapy Induced Nausea and Vomiting - Pipeline by INSYS Therapeutics, Inc., H2 2015
Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Chemotherapy Induced Nausea and Vomiting - Pipeline by Merck & Co., Inc., H2 2015
Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd., H2 2015
Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd., H2 2015
Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H2 2015
Chemotherapy Induced Nausea and Vomiting - Pipeline by Teikoku Pharma USA, Inc., H2 2015
Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Chemotherapy Induced Nausea and Vomiting Therapeutics - Recent Pipeline Updates, H2 2015
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H2 2015
Chemotherapy Induced Nausea and Vomiting - Dormant Projects (Contd..1), H2 2015
Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2015
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report